Dr. Marcelo Di Carli, a radiology professor at Harvard Medical School, says a number of radiopharmaceuticals under development hold potential for cardiac imaging. PET agent F-18 flurpiridaz has shown high myocardium extraction in midstage clinical studies, and it can be distributed on a unit-dose basis, meaning it would be available to more practices and patients. Meanwhile, iodine-123 metaiodobenzylguanidine, which is being developed for SPECT imaging, may be effective in improving risk stratification for heart failure patients, Di Carli added. The approach evaluates cardiac sympathetic innervation. Agents that measure proteins linked to inflammation in atherosclerotic plaques are also coming.
What's coming in cardiovascular imaging?
SmartBrief Job Listings for Health Care
|Regional Sales Consultant (Contract Position)||
|Business Developer, Strategic Partnerships (Healthcare)||
Geisinger Health System
|Director Health Plans||
Accreditation Association for Ambulatory Health Care (AAAHC)
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)